Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania. Show more

Location: 1717 Langhorne Newtown Road, Langhorne, PA, 19047, United States | Website: https://www.savarapharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

731.1M

52 Wk Range

$1.89 - $4.29

Previous Close

$4.23

Open

$4.25

Volume

172,110

Day Range

$4.06 - $4.25

Enterprise Value

486.5M

Cash

146.9M

Avg Qtr Burn

-24.85M

Insider Ownership

5.38%

Institutional Own.

98.05%

Qtr Updated

06/30/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Molgramostim Details Autoimmune Pulmonary Alveolar Proteinosis (aPAP)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.